Invivyd, Inc. (IVVD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Invivyd, Inc. (IVVD) Healthcare & Pipeline Overview

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on antibody-based solutions for infectious diseases, with its lead candidate ADG20 (adintrevimab) in Phase 3 trials for COVID-19 treatment and prevention. The company collaborates with Adimab, LLC and the Scripps Research Institute to advance its pipeline.

What Is the Investment Thesis for IVVD?

Invivyd, Inc. presents a focused investment opportunity within the biotechnology sector, primarily driven by the potential success of its lead product candidate, ADG20 (adintrevimab). Currently in Phase 3 clinical trials, positive results could lead to rapid regulatory approval and commercialization, addressing a significant need for COVID-19 treatment and prevention. The company's collaborations with Adimab, LLC and the Scripps Research Institute enhance its research and development capabilities, potentially expanding its pipeline beyond ADG20. With a market capitalization of $229M, Invivyd offers a high-risk, high-reward profile, contingent on clinical trial outcomes and regulatory approvals. However, the company's negative profit margin of -98.2% indicates a reliance on future product revenue to achieve profitability.

Based on FMP financials and quantitative analysis

IVVD Key Highlights

Lead product candidate ADG20 (adintrevimab) is in Phase 3 clinical trials for COVID-19 treatment and prevention.

• Market capitalization of $229M reflects investor expectations for ADG20's potential.
• Gross margin of 93.0% suggests strong pricing power if ADG20 is successfully commercialized.
• Profit margin of -98.2% indicates significant ongoing R&D expenses and a lack of current product revenue.
• Collaboration agreements with Adimab, LLC and the Scripps Research Institute provide access to advanced antibody discovery and vaccine research technologies.

Who Are IVVD's Competitors?

IVVD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are IVVD's Key Strengths?

Promising lead product candidate (ADG20) in Phase 3 trials.

• Strong gross margin potential (93.0%).
• Strategic collaborations with Adimab and Scripps.
• Experienced leadership team.

What Are IVVD's Weaknesses?

High R&D expenses and negative profit margin (-98.2%).

• Reliance on the success of a single product candidate.
• Limited commercial infrastructure.
• Relatively short operating history (founded in 2020).

What Could Drive IVVD Stock Higher?

Announcement of Phase 3 clinical trial results for ADG20 (adintrevimab).

• Potential regulatory approval of ADG20 by the FDA.
• Expansion of research collaborations with Adimab and Scripps.
• Progress in developing new antibody-based solutions for other infectious diseases.

What Are the Key Risks for IVVD?

Listing risk — at $0.7759 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.

• Financial-distress signal — its Altman Z-Score of -3.57 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-53.5%) — the business is not currently generating profit on shareholder capital.
• Unfavorable clinical trial outcomes for ADG20.
• Regulatory delays or rejection of ADG20.
• Competition from other pharmaceutical companies developing infectious disease therapies.
• High R&D expenses and reliance on future product revenue.

What Are the Growth Opportunities for IVVD?

• Growth opportunity 1: Successful completion of Phase 3 clinical trials for ADG20 (adintrevimab) and subsequent regulatory approval represent a major growth catalyst. The market for COVID-19 treatments and preventatives remains significant, even as the pandemic evolves. Positive trial data could lead to rapid commercialization and revenue generation, establishing Invivyd as a key player in the infectious disease space. Timeline: Anticipated regulatory submissions within the next 12-18 months, contingent on trial results.
• Growth opportunity 2: Expanding the pipeline beyond ADG20 through strategic collaborations and internal research efforts. The company's partnerships with Adimab, LLC and the Scripps Research Institute provide access to novel antibody discovery platforms and vaccine research capabilities. Diversifying the pipeline into other infectious diseases could mitigate the risk associated with relying solely on ADG20. Timeline: Initiate preclinical studies for new candidates within the next 24 months.
• Growth opportunity 3: Securing government contracts and funding for the development and distribution of ADG20. Governments worldwide are investing heavily in pandemic preparedness and response. Obtaining contracts for ADG20 could provide significant financial support and ensure access to key markets. Timeline: Pursue government contracts in the next 6-12 months.
• Growth opportunity 4: Exploring potential applications of ADG20 beyond COVID-19, such as for the treatment of other beta coronaviruses. The antibody's mechanism of action may offer broader applicability, expanding its market potential. Timeline: Initiate preclinical studies to evaluate ADG20's efficacy against other coronaviruses within the next 18-24 months.
• Growth opportunity 5: Establishing strategic partnerships with larger pharmaceutical companies for the commercialization and distribution of ADG20. Leveraging the established infrastructure and market access of a major pharmaceutical company could accelerate ADG20's adoption and maximize its revenue potential. Timeline: Pursue partnership discussions following positive Phase 3 trial results.

What Threats Does IVVD Face?

• Unsuccessful clinical trial results.
• Regulatory hurdles and delays.
• Competition from established pharmaceutical companies.
• Patent expiration and biosimilar competition.

What Are IVVD's Competitive Advantages?

• Proprietary antibody technology and intellectual property.
• Strategic collaborations with leading research institutions.
• Clinical trial expertise and regulatory knowledge.
• Potential first-mover advantage in specific infectious disease markets.

What Does IVVD Do?

Invivyd, Inc., formerly Adagio Therapeutics, Inc., is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing antibody-based solutions for infectious diseases. Founded in 2020 and based in Waltham, Massachusetts, the company is driven by the need to address unmet medical needs in the face of evolving viral threats. Its lead product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials for both the treatment and prevention of coronavirus disease. Invivyd's approach involves strategic collaborations to enhance its research and development capabilities. The company has a collaboration agreement with Adimab, LLC, focusing on the discovery and optimization of proprietary antibodies. Additionally, Invivyd partners with the Scripps Research Institute to conduct research activities aimed at identifying vaccine candidates for the prevention, diagnosis, or treatment of influenza and beta coronaviruses. This collaborative ecosystem allows Invivyd to leverage external expertise and accelerate the development of innovative solutions. The company's focus remains on addressing critical gaps in the treatment and prevention of infectious diseases, particularly those with pandemic potential.

What Products and Services Does IVVD Offer?

• Discovers and develops antibody-based solutions for infectious diseases.
• Focuses on addressing unmet medical needs in the face of evolving viral threats.
• Conducts Phase 3 clinical trials for ADG20 (adintrevimab) for COVID-19 treatment and prevention.
• Collaborates with Adimab, LLC for antibody discovery and optimization.
• Partners with the Scripps Research Institute for vaccine research.
• Aims to commercialize innovative therapies for infectious diseases.

How Does IVVD Make Money?

• Develops and patents antibody-based therapeutics.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA.
• Commercializes approved therapies through direct sales or partnerships.

What Industry Does IVVD Operate In?

Invivyd, Inc. operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy clinical trial processes, and stringent regulatory requirements. The market for infectious disease treatments is substantial, driven by both seasonal outbreaks and pandemic threats. Companies like Regeneron and Gilead Sciences are established players in this space. Invivyd's focus on antibody-based solutions positions it to compete in a market demanding innovative therapies, but success hinges on positive clinical trial outcomes and regulatory approvals.

Who Are IVVD's Key Customers?

• Hospitals and healthcare providers treating patients with infectious diseases.
• Government agencies responsible for public health and pandemic preparedness.
• Patients seeking treatment and prevention options for infectious diseases.

Invivyd, Inc. (IVVD) Valuation Context

Valued at $229M, IVVD is classified as a micro-cap stock. Relative to its peer group, IVVD's quantitative score of 15/100 is below the peer average of 75/100.

IVVD Revenue & Earnings Trend

In Q2 FY2026, IVVD generated $14.3M in top-line revenue, marking a sequential increase of 3.9%. The company recorded a net loss of $44.4M, with diluted EPS of $-0.14. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, IVVD averaged $-0.10 in diluted EPS.

Company Profile

Invivyd, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New Haven, US. The company is led by CEO William E. Duke Jr.. IVVD has traded publicly since 2021.

Return on equity for Invivyd, Inc. stands at -53.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -32.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -31.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -29.3%, the inverse of the P/E and a quick read on earnings relative to price.

Invivyd, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.57 places it in the distress zone, a signal of elevated financial risk.

Invivyd, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 55.6% below estimates on average.

Over the past six months, Invivyd, Inc. insiders filed 29 SEC Form 4 transactions — 15 sales and 14 purchases. On net that is roughly 12.0M shares acquired (about $11.1M) — insiders putting money in tends to read as conviction.

IVVD Financials

IVVD Latest News

IVVD Analyst Consensus

IVVD MoonshotScore

Invivyd, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources